Oral rehydration of malnourished children with diarrhoea and dehydration: A systematic review [version 3; peer review: 2 approved]

Kirsty A. Houston¹,², Jack G. Gibb¹,², Kathryn Maitland¹,²

¹Department of Paediatrics, Faculty of Medicine, Imperial College, London, W2 1PG, UK
²KEMRI-Wellcome Trust Research Programme, Kilifi, 80108, Kenya

Abstract

Background: Diarrhoea complicates over half of admissions to hospital with severe acute malnutrition (SAM). World Health Organization (WHO) guidelines for the management of dehydration recommend the use of oral rehydration with ReSoMal (an oral rehydration solution (ORS) for SAM), which has lower sodium (45mmols/l) and higher potassium (40mmols/l) content than old WHO ORS. The composition of ReSoMal was designed specifically to address theoretical risks of sodium overload and potential under-treatment of severe hypokalaemia with rehydration using standard ORS. In African children, severe hyponatraemia at admission is a major risk factor for poor outcome in children with SAM complicated by diarrhoea. We therefore reviewed the evidence for oral rehydration therapy in children with SAM.

Methods: We conducted a systematic review of randomised controlled trials (RCTs) on 18th July 2017 comparing different oral rehydration solutions in severely malnourished children with diarrhoea and dehydration, using standard search terms. The author assessed papers for inclusion. The primary endpoint was frequency of hyponatraemia during rehydration.

Results: Six RCTs were identified, all published in English and conducted in low resource settings in Asia. A range of ORS were evaluated in these studies, including old WHO ORS, standard hypo-osmolar WHO ORS and ReSoMal. Hyponatraemia was observed in two trials evaluating ReSoMal, three children developed severe hyponatraemia with one experiencing convulsions. Hypo-osmolar ORS was found to have benefits in time to rehydration, reduction of stool output and duration of diarrhoea. No trials reported over-hydration or fatalities.

Conclusions: Current WHO guidelines strongly recommend the use of
ReSoMal based on low quality of evidence. Studies indicate a significant risk of hyponatraemia on ReSoMal in Asian children, none have been conducted in Africa, where SAM mortality remains high. Further research should be conducted in Africa to evaluate optimal ORS for children with SAM and to generate evidence based, practical guidelines.

**Keywords**
malnutrition, gastroenteritis, dehydration, rehydration, systematic review, Africa, Asia, oral rehydration solution

This article is included in the KEMRI | Wellcome Trust gateway.
Introduction

In Africa, diarrhoea has been reported to complicate 49% of admissions to hospital of children with severe acute malnutrition (SAM), and a further 16% develop diarrhoea within 48 hours of admission. The in-hospital case fatality in children with SAM admitted with diarrhoea is high, 19%, versus 9% in those without diarrhoea, \( \chi^2 = 17.6, p<0.001 \) and no prospect of improvement has been demonstrated over the last decade\(^6\).

Management of children with SAM complicated by diarrhoea focuses on exclusive oral or nasogastric (NG) rehydration, and limits intravenous rehydration to those complicated by advanced hypovolaemic shock or for those with severe dehydration who are unable to take or tolerate oral fluid\(^7\). The World Health Organization (WHO) guidelines are used widely in low resource settings as the standard of care, recommending that oral or NG rehydration fluids can be commenced for any child with SAM and diarrhoea (defined as three or more loose, watery stools) (Table 1). The guidelines do not allow for an assessment of severity of dehydration in children with SAM, indicating that dehydration is often difficult to diagnose in malnourished children because the clinical signs usually relied on to diagnose dehydration are similar to those found in severe wasting without dehydration\(^8\). However, the available evidence contradicts this contention. In a prospective study involving 920 unselected Kenyan children admitted to hospital with SAM, sepsis, signs of severe dehydration (secondary to diarrhoea) and hypovolaemic shock were common complications and were triage features associated with high early fatality (>20% mortality)\(^9\). Another prospective observational study conducted at the same centre examined in more detail diarrhoea in malnutrition, and multivariate analysis identified bacteraemia (odds ratio 6.7 (95% confidence interval 2.5-17.8 p<0.001)) and hyponatraemia (odds ratio 4.9 (95% CI 2.2-11.1 p<0.001)) as key risk factors for mortality\(^1\). Only a very small number of children with signs of advanced shock are recommended to receive intravenous (IV) fluids, 15ml/Kg of hypotonic fluid, followed by a blood transfusion if there is no improvement (Table 1). Outcomes in this group remains very unsatisfactory (reviewed by Houston et al., 2017)\(^1\).

Recommendations suggest avoiding IV fluids in children with SAM due to concerns about the ability of these children to handle significant volume loads and potential susceptibility to fluid overload and cardiac failure. However, available evidence suggests that the perturbations of myocardial function are related to complications of sepsis, shock and severe dehydration and not due to ‘heart failure’.\(^10\) A recent publication by Obonyo et al. 2017 demonstrated ‘fluid responsive’ myocardial indices following rehydration in children with SAM and hypovolaemic shock\(^11\).

Types of Oral Rehydration Solutions

The original or ‘old’ oral rehydration solution (ORS) recommended by WHO was designed largely to treat children with cholera and thus had a high sodium content (since cholera is a secretory diarrhoea with large losses of both sodium and water). At that time WHO guidance advised that children with SAM should be given a modified version of oral rehydration solution (ORS) called ReSoMal (rehydration solution for malnutrition), which has lower sodium, higher potassium and glucose and lower osmolarity than Old WHO ORS (Table 2)\(^6\). This was due to concerns that ‘children with bilateral pitting oedema typically have high intracellular sodium and are therefore inclined to retain fluids’ and ‘are prone to fluid retention and susceptible to fluid changes’, thereby predisposing the child to fluid overload and heart failure\(^12\). Whilst this was suggested by Wharton et al., who

<table>
<thead>
<tr>
<th>Table 1. Current recommendations for treatment of severely malnourished children with severe dehydration (WHO 2013)(^6)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No shock</strong></td>
</tr>
<tr>
<td>Initial</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Subsequent</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

*Shock is defined as the presence of all three of the following signs: Prolonged capillary refill time (>3seconds), temperature gradient and weak and fast pulse. ReSoMal – rehydration solution for malnutrition, PO/NG – Oral or nasogastric route, RL+5% – Ringers lactate and 5% dextrose, 1/2SD+5% - ½ strength Darrow’s solution and 5% dextrose, F75 – primary feeding formula for children with SAM
reported an excess of heart failure in children receiving a high energy milk to which sodium was added\textsuperscript{13}, apparently to improve acceptability in all children (including those without diarrhoea) the sodium content was probably higher and the milk given over a longer period of time than they would have received if they were only being rehydrated. Thus, this cannot be extrapolated to inform management of rehydration in children with SAM. Furthermore, an observational study has reported that in SAM children receiving liberal ReSoMal leads to excess mortality due to heart failure due to excessive sodium intake as a reference source to support these recommendations. However, this does not qualify as sufficient evidence to inform the management of African children who have diarrhoea\textsuperscript{1}. Other than these observations we are have found no physiological data published to support this contentious opinion that children with severe malnutrition are prone to sodium overload, even for the sub group of greatest concern, kwashiorkor\textsuperscript{15,16}.

The current standard (hypo-osmolar) WHO ORS, with lower sodium and glucose content, was developed in order to reduce the intensity of diarrhoea in children. A meta-analysis of 8 trials, showed that reduced osmolality ORS was associated with fewer unscheduled intravenous fluid infusions (the primary endpoint) compared with WHO standard ORS and stool output, reported in eleven trials, was less in the reduced osmolarity ORS group\textsuperscript{17}. Hypo-osmolar ORS has now been adopted into practice and has largely replaced the old ORS formulation and is recommended in current WHO paediatric management guidelines\textsuperscript{12}. The Standard (hyposmolar) WHO ORS recommended for non-SAM children is therefore closer in composition to ReSoMal with respect to sodium content but has a much lower osmolarity (due to the lower glucose content) than ReSoMal which means theoretically that it may have less potential to exacerbate stool volume and diarrhoea in children with SAM.

The ‘strong’ recommendations for rehydration of children with SAM are informed by a nutritional specialist group for the WHO and are based on expert opinion, since the review of the data indicated low quality of evidence\textsuperscript{6}. The most recent updates to WHO guidelines in 2013 did not revise any of their recommendations, with the exception of the addition of a single 15ml/kg bolus of hypotonic intravenous fluid for severely dehydrated children unable to tolerate oral rehydration (as per shock management)\textsuperscript{6}. No further IV rehydration beyond this was considered, with most rehydration strategies focused on oral rehydration. Owing to the poor outcomes recognised in African children with SAM complicated by diarrhoea, we therefore conducted a systematic review of the current available evidence underlying oral rehydration solutions for children with dehydration and severe acute malnutrition.

**Objectives**

To conduct a critical appraisal of available evidence evaluating the use of ReSoMal and hypo-osmolar ORS in the treatment of dehydration in children with SAM.

**Methods**

We did not publish a protocol prior to conducting this review. A search of online literature was performed. There were predetermined criteria, as detailed below for eligibility of studies, data outcomes, and an assessment of risk of bias and study method quality in each of the identified studies.

**Selection criteria**

**Population.** Children aged 0 to 12 years with SAM requiring oral rehydration solution for management of dehydration secondary to gastroenteritis. We used the WHO definitions for malnutrition (Weight-for-height Z score (WHZ) < -3, mid-upper arm circumference (MUAC) < 115mm or oedema consistent with kwashiorkor), gastroenteritis (dehydrating diarrhoea, > 3 loose stools per day) and for dehydration. We excluded studies with chronic or persistent diarrhoea lasting ≥ 14 days.

**Intervention and comparison.** All studies that compare two or more different ORS were included. Studies were excluded if they considered rehydration in children without severe malnutrition, only considered rehydration via the IV route or only included patients with congenital heart disease, trauma, or diabetic ketoacidosis.

**Outcome.** Clinical trials that reported on any outcomes were included. The primary outcome for this review was frequency of hyponatraemia (sodium concentration < 135mmol/L) during and after rehydration therapy. Secondary outcomes were all cause mortality, time to rehydration, stool output, frequency of fluid overload and frequency of oral rehydration failure.

**Study design.** Only randomised-controlled trials (RCTs) were included.

**Search methods**

**Online database search.** A comprehensive literature search of the following databases was conducted on the 18\textsuperscript{th} July 2017 using the English search terms ‘malnutrition’ AND ‘children’ AND ‘rehydration’ AND ‘oral’:

- PubMed/ Medline
- Global Health Library (Virtual Health Library)
- Cochrane Database of Systematic Reviews

---

**Table 2. Comparison of formulations of oral rehydration solution (ORS).**

<table>
<thead>
<tr>
<th></th>
<th>Old WHO ORS</th>
<th>Standard (hypo-osmolar) WHO ORS</th>
<th>ReSoMal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osmolarity (mOsm/L)</td>
<td>311</td>
<td>245</td>
<td>300</td>
</tr>
<tr>
<td>Sodium Mmol/l</td>
<td>90</td>
<td>75</td>
<td>45</td>
</tr>
<tr>
<td>Potassium Mmol/l</td>
<td>20</td>
<td>20</td>
<td>40</td>
</tr>
<tr>
<td>Chloride Mmol/l</td>
<td>80</td>
<td>65</td>
<td>76</td>
</tr>
<tr>
<td>Glucose Mmol/l</td>
<td>111</td>
<td>75</td>
<td>125</td>
</tr>
</tbody>
</table>
• Cochrane Central Register of Controlled Trials
• ClinicalTrials.gov
• The WHO International Clinical Trials Registry Portal (ICTRP) search portal

Each of the eligible studies was assessed and a manual review of the reference lists carried out. Additionally, a Google search was performed.

The authors screened the results of the literature search for studies that met the inclusion criteria as determined by the PICOS outline.

**Results**

**Study selection**

The search produced 432 studies (Figure 1). After screening and evaluation, six studies were identified that investigated ORS in children with SAM complicated by dehydration, incorporating a total of 686 children. All six of these studies were conducted in Asia, four of which were conducted at the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR, B)\(^1\)\(^-\)\(^4\) and two in India (New Delhi\(^5\) and Calcutta\(^6\)). One study included children with and without SAM\(^7\), but reported independently on outcomes for children with SAM. One study included children with cholera only\(^8\) (see Box 1 for further details). There was moderate heterogeneity in the population eligibility criteria, sample size, and methods employed by each study, and in their results. Table 3 and Table 4 show the setting, methodology and

---

**Box 1. Management of cholera in children with SAM.**

<table>
<thead>
<tr>
<th>WHO guidelines</th>
<th>Children with SAM should be rehydrated slowly, either orally or by nasogastric tube, using WHO standard oral rehydration solution (ORS), 5ml/Kg every 30 minutes for the first 2 hours and then 5–10ml/Kg/hour up to a maximum of 10 hours. ReSoMal should not be given if the child has suspected cholera or has profuse watery diarrhoea. Intravenous fluid should not be used unless the child has shock and cannot be rehydrated orally or by nasogastric tube.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence for oral rehydration</td>
<td>This review includes 259 (out of a possible total of 665) patients that had cholera (39%) in five of the six studies (Kumar et al., 2015, did not report on numbers with cholera). One study included only children with cholera and two further studies presented sub-analyses on patients with cholera. Relevant findings: Alam et al. (2009)(^9) included ONLY patients with cholera and reported that the only significant difference was a reduction in stool output with children receiving the rice-based ORS. Alam et al. (2000)(^10) reported no significant difference in frequency of hyponatraemia and significantly less hypo-osmolar ORS consumed than standard ORS. Alam et al. (2003)(^11) showed no significant differences in hyponatraemia between patients with cholera treated with ReSoMal or standard ORS. Notably, the patient who developed hyponatraemic seizures did not have cholera.</td>
</tr>
<tr>
<td>Implications in practice</td>
<td>There appears to be no additional significant benefit to using hypo-osmolar ORS or ReSoMal in comparison with standard WHO ORS. Guidelines for children with SAM and suspected or confirmed cholera are identical to those with non-cholera diarrhoea other than the ORS used. Cholera is a secretory diarrhoea with high stool volume output and the current restrictive guidelines may therefore result in under treatment of children with dehydration.</td>
</tr>
</tbody>
</table>

---

**Figure 1. Flow diagram for selection of studies and reasons for study exclusion.**
<table>
<thead>
<tr>
<th>Year</th>
<th>Location</th>
<th>Study type</th>
<th>Sample size</th>
<th>Population</th>
<th>Sample</th>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
<th>Comparison (number in group)</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>ICDDR, B, Dhaka Hospital</td>
<td>RCT (Double blinded)</td>
<td>170</td>
<td>Children aged 6 months and above</td>
<td>81 (WHO ORS 40)</td>
<td>Children with acute (&lt;4 days duration) diarrhoea with dehydration and one of the following: i) non-cholera diarrhoea, aged 3 months to 5 years; and ii) all children above 3 months with clinical suspicion of cholera</td>
<td>Children with evidence of systemic infection, encephalopathy, electrolyte imbalance, convulsion or invasive diarrhoea</td>
<td>Old WHO ORS (40) vs. Hypo-osmolar WHO ORS (41)</td>
<td>Time to rehydration, stool frequency and duration of diarrhoea, time to discharge</td>
</tr>
<tr>
<td>2003</td>
<td>ICDDR, B, Dhaka Hospital</td>
<td>RCT (Double blind)</td>
<td>130</td>
<td>Children aged 6 to 36 months</td>
<td>75</td>
<td>Children with severe malnutrition (WFH &lt;70% NCHS median or bilateral pedal oedema) and acute watery diarrhoea (&lt;10 days)</td>
<td>Children with bloody diarrhoea, severe dehydration requiring IV fluids or signs of severe infection</td>
<td>ReSoMal (75) vs. old WHO-ORS (75)</td>
<td>Primary: Frequency of over hydration and number who corrected hypokalaemia at 24 and 48 hours; Secondary: number of children free of weight for length of SAM</td>
</tr>
<tr>
<td>2009</td>
<td>ICDDR, B, Dhaka Hospital</td>
<td>RCT (Not blinded due to visible differences in the ORS)</td>
<td>126</td>
<td>Children aged 6 to 36 months</td>
<td>63</td>
<td>Children with severe malnutrition (WFH/WFA &lt;-3 Z score with or without pedal oedema) with acute diarrhoea (3 or more watery stools for 24 hours, lasting &lt;7 days)</td>
<td>Children with bloody diarrhoea, severe diseases (pneumonia, meningitis)</td>
<td>Hypo-osmolar ORS with (63) and without (63) additional 15g/L PHGG (partially hydrolysed guar gum)</td>
<td>Duration of diarrhoea, proportion recovered within 72 hours, daily stool output and recovery from severe malnutrition</td>
</tr>
<tr>
<td>2015</td>
<td>ICDDR, B, Dhaka Hospital</td>
<td>RCT (Double blind)</td>
<td>64</td>
<td>Children aged 6 to 48 months</td>
<td>32</td>
<td>Children with severe acute malnutrition (WHO case definition) and acute diarrhoea (3 or more watery stools for 24 hours, lasting &lt;7 days)</td>
<td>Children with recent history of diarrhoea (1 month), previous antibiotic use, oral rehydration during this episode, obvious parental infection, exclusively breastfed and if they had kwashiorkor</td>
<td>Low-osmolarity ORS with added potassium versus modified ReSoMal (32)</td>
<td>Number of children developing hypokalaemia, frequency of hypokalaemia, stool frequency and ORS consumption and time to rehydration</td>
</tr>
</tbody>
</table>
Table 4. Methodology and results of included studies.

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Methodology</th>
<th>Frequency of hyponatraemia</th>
<th>Other outcomes (mortality, time to rehydration, time to discharge, stool output, frequency of fluid overload and frequency of treatment failure)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alam et al., 2000&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Serially allotted the study ORS packet (pre-made and ordered by pharmacy according to randomisation) – randomisation process not specified. Outcomes not pre-specified. If severely dehydrated they received 50ml/Kg RL in 1 hour before inclusion in the study. Then 75ml/Kg ORS over 4 hours. Serial clinical assessments of dehydration.</td>
<td>No significant difference in serum sodium</td>
<td>Shorter duration of rehydration in hypomolar ORS group although not significant (10.95 hours vs. 11.72 hours, p=0.32, 95% CI 0.55-0.97)</td>
</tr>
<tr>
<td>Alam et al., 2003&lt;sup&gt;9&lt;/sup&gt;</td>
<td>Children enrolled and randomised (list provided by WHO Geneva and serially numbered). Blinding well detailed. Clinical history taken, blood, and stool samples taken, plus urine and CXR if indicated. WHO standard protocol followed. Children received 10ml/Kg/h first 2 hours and then 5ml/Kg/hour over 10–12 hours until deficit corrected. On-going stool losses also accounted for.</td>
<td>3 children in the ReSoMal group developed severe hyponatraemia by 24 hours and one had hyponatraemic convulsions (serum sodium 108mmol/L). Serum sodium was lower at 24 and 48hrs in ReSoMal group (p&lt;0.01 and p&lt;0.001 respectively)</td>
<td>Children equally and adequately well hydrated (ReSoMal vs. WHO-ORS, 76% vs. 81%, p=0.68)</td>
</tr>
<tr>
<td>Alam et al., 2009&lt;sup&gt;9&lt;/sup&gt;</td>
<td>Severely dehydrated children were administered 100ml/Kg IV ‘cholera-saline’ for 4–6 hrs prior to randomisation. If eligible, children randomised to one of 3 ORS solutions (list prepared by independent statistician). Clinical assessment at admission, blood, urine and stool samples obtained. ORS 100ml/KG over 6 hours, plus additional ORS if high purging rate. Continued until cessation of diarrhoea. Standard protocol for SAM followed. Followed up for minimum 6 weeks.</td>
<td>Serum sodium at baseline not significantly different and subsequent hypo/hypernatraemia not reported</td>
<td>Time to rehydration not significantly different between groups. All were rehydrated within 6 hours. None developed over-hydration or heart failure. Stool output and ORS intake in first 24 hours was significantly less in rice ORS group (p=0.004 and p=0.002 respectively). Urine output at 12 hours not significantly different. Duration of diarrhoea and time to attain 80% median weight/length not different. No significance difference in treatment failure (p=0.785)</td>
</tr>
<tr>
<td>Risk of bias</td>
<td>Methodology</td>
<td>Frequency of hyponatraemia</td>
<td>Other outcomes (mortality, time to rehydration, time to discharge, stool output, frequency of fluid overload and frequency of treatment failure)</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------</td>
<td>---------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Alam et al., 2015&lt;sup&gt;23&lt;/sup&gt;</td>
<td>Low</td>
<td>Eligibility confirmed and then child randomised 1:1 to ORS (list provided by independent statistician and held by pharmacists). Children with severe dehydration were treated with IV fluids and then randomised as soon as they were out of hypovolaemic shock and signs of severe dehydration resolved (but &lt;4hours). Clinical assessments, blood and urine samples. Otherwise followed WHO protocol.</td>
<td>Serum sodium at baseline not significantly different and subsequent hypo/hypernatraemia not reported</td>
</tr>
<tr>
<td>Dutta et al., 2001&lt;sup&gt;23&lt;/sup&gt;</td>
<td>Low-moderate</td>
<td>Eligibility checked, consented and clinical assessment done. Computer generated randomisation table used for allocation of ORS, held by independent individual who provided ORS packets. Blood and stool samples taken. Outcomes not pre-specified</td>
<td>Mean serum sodium on recovery was within normal range in both groups</td>
</tr>
<tr>
<td>Kumar et al., 2015&lt;sup&gt;23&lt;/sup&gt;</td>
<td>Low</td>
<td>Enrolment, randomisation (block randomisation by computer generated sequence), then clinical assessment, and blood samples taken. Other treatment as per WHO-guidelines. Statistical analysis specified</td>
<td>Greater proportion of children developed hyponatraemia in ReSoMal group (15.4% vs. 1.9%, p=0.03)</td>
</tr>
</tbody>
</table>
features of the included studies and their results. Table 5 shows the formulations of ORS used in the studies.

**Risk of bias**
The quality of each of the included studies was assessed for risk of bias using the Cochrane collaboration’s tool in order to evaluate validity. Four studies had a low risk of bias and two had low-moderate risk of bias due to lack of pre-determined outcomes in the methods.

**Outcomes**

**Primary outcome**

**Hyponatraemia**

This outcome was available from four studies. Two of these compared old WHO ORS formulations with hypo-osmolar formulations (Alam et al. 2000 and Dutta et al. 2001). Alam et al. (2000) only reported baseline chemistry; however Dutta et al. (2001) found no significant differences in sodium at baseline and recovery, with sodium levels remaining within normal limits at recovery for both formulations of ORS. Two studies (Alam et al. 2003 and Kumar et al. 2015) compared ReSoMal with old WHO ORS: the first (Alam et al. 2003) compared ReSoMal with old WHO ORS and found that 1/64 (2%) in the ORS group developed severe hyponatraemia (Na ≤ 120mmol/L) compared to 3/62 (5%) children receiving ReSoMal, with one of these three experiencing hyponatraemic seizures (serum sodium 108mmol/L). Serum sodium was similar at baseline in both arms (p=0.51), but was lower at 24 and 48 hours in ReSoMal group (p<0.01 and p<0.001 respectively). The second (Kumar et al. 2015) compared ReSoMal with hypo-osmolar ORS and found that a greater proportion of children in the ReSoMal group developed hyponatraemia (15.4% vs. 1.9%, p=0.03).

**Secondary outcomes**

**Mortality**

This outcome was reported in two studies. Alam et al. (2003) and Alam et al. (2009) reported no deaths during the trial periods.

**Time to rehydration or recovery**

Five of the studies reported on time to rehydration. One study (Alam et al. 2003) found that there was no significant difference in time to rehydration (time to attain 80% of weight for length or height) between groups. Two studies evaluating old WHO ORS versus hypo-osmolar ORS (Alam et al. 2000 and Dutta et al. 2001) found that there was a faster recovery (passage of 2 consecutive formed stools or no diarrhoea for 12 hours) in the group receiving hypo-osmolar ORS compared to old WHO ORS (36 vs. 53 hours, p=0.001). Alam et al. (2000) reported average time to rehydration (though how this was assessed was not defined) of 10.95 hours in hypo-osmolar group versus 11.7 hours in old WHO-ORS group (p=0.32). Dutta et al. (2001) reported faster time to recovery in hypo-osmolar group. Of the two studies comparing ReSoMal with WHO ORS (old or hypo-osmolar), one study reported shorter time to rehydration in ReSoMal group (Kumar et al. 2015) (16.1 hours compared with 19.6 hours in group receiving hypo-osmolar ORS, p=0.036), whilst the Alam et al. (2003) trial reported that the groups were equally well rehydrated by both regimes.

<table>
<thead>
<tr>
<th>Used in study</th>
<th>Modified WHO ORS</th>
<th>Hypo-osmolar ORS</th>
<th>Modified ReSoMal</th>
<th>Glucose-ORS</th>
<th>Glucose-ORS and ARS</th>
<th>Rice-ORS</th>
<th>Hypo-osmolar ORS</th>
<th>Old WHO ORS</th>
<th>Standard (hypo-osmolar) WHO ORS</th>
<th>ReSoMal</th>
</tr>
</thead>
</table>

*ARS – Amylase-Resistant starch *PHGG – partially hydrolysed guar gum ORS - Oral rehydration solution - not presented in paper
Stool output
All of the studies reported on stool output, either by measuring weight of stools or nappies (Alam et al. 2003, 2009, 2015 and Dutta 2015) or recording frequency (Alam et al. 2000 and Kumar et al. 2015). Of the two studies comparing standard with hypo-osmolar ORS, both found that the stool output was significantly less in the group receiving hypo-osmolar ORS (Alam et al. 2000 found that daily stool frequency was 4.27 compared with 5.86 episodes, p<0.05, and Dutta et al. (2001) found that stool output was 52.3 versus 96.6 g/Kg/day, p=0.0001). Alam et al. (2009) and (2001) found that stool weight (collected in a bucket or in pre-weighed nappies and weighed) was significantly less when children received rice-based ORS (compared with glucose based ORS) or partially hydrolysed guar gum (PHGG) added to ORS (compared with hypo-osmolar ORS). Alam et al. (2000) and Kumar et al. (2015) reported that stool frequency was similar between the ReSoMal and hypo-osmolar ORS groups.

Frequency of fluid overload
Three studies reported on frequency of fluid overload. Alam et al. (2003) reported no significant difference in over-hydration with each of the three formulations of ORS (defined as >5% weight gain after correction of dehydration at any time during the study period with any of the following signs: periorbital oedema/puffy face, increased heart rate (>160/min) or increased respiration (>60/min)). Both Alam et al. (2009) and Kumar et al. (2015) did not report signs of fluid overload.

Oral rehydration failure
This outcome was available with varying definitions from the 5 studies. Alam et al. (2003) and (2015) Kumar et al. (2015) reported the number of patients requiring IV fluids after randomisation. There were no significant differences in this outcome between groups receiving ORS (hypo-osmolar or old WHO) and ReSoMal, nor did addition of PHGG to ORS reduce the treatment failure rate. Alam et al. (2009) defined failure as on-going diarrhoea 7 days after randomisation and found similar numbers (one and two patients from the glucose-ORS and glucose-ORS plus ARS groups, respectively) in each group. Dutta et al. (2001) reported the number of patients who failed to recover after 5 days and again found no difference between groups receiving hypo-osmolar and old WHO ORS.

Discussion
These studies evaluated a number of different combinations of ORS formulations, including old WHO ORS (sodium level 90mmol/L), standard/current WHO hypo-osmolar ORS (sodium 75mmol/L) and ReSoMal (sodium 45mmol/L), with minor variations within the composition across studies (PHGG and Amylase-Resistant Starch). All studies used conventional definitions for diagnosis of severe acute malnutrition, i.e. using WHO or NCHS criteria, and varying criteria for assessment of severity of dehydration. All of the study interventions were blinded to patients and clinicians except in the Kumar et al. (2015) and Alam et al. (2009) trials. This is important to mention as strength of the design of the trial, since a number of the outcomes were subjective, in particular, the secondary outcomes: time to rehydration or recovery, frequency of fluid overload and treatment failure. However, Kumar et al. (2015) used frequency of hyponatraemia as the primary outcome - an objective, quantitative outcome. Notably, none of these studies assessed ORS therapy in the community, and all the reported studies have been conducted in Asia, and in none of the trials were there any case fatalities. Of note, none of the trials were conducted in African children, who have a much higher mortality rate when SAM is complicated by diarrhoea.

There was no improvement in frequency of hyponatraemia with rehydration when comparing current standard WHO hypo-osmolar with old WHO ORS. There were no differences in between-group rehydration failure rates within any of the studies; no rehydration solution demonstrated superiority for this outcome. However, use of standard hypo-osmolar ORS appeared to have advantages in terms of reduction of stool output, duration of diarrhoea and time to rehydration, when compared with old WHO ORS.

Use of ReSoMal, when compared with old WHO ORS and standard hypo-osmolar WHO ORS resulted in greater proportions of children developing or worsening of hyponatraemia after rehydration treatment. In one study, this was associated with severe hyponatraemia in three children and development of hyponatraemic seizures in one of these children. ReSoMal did however correct hypokalaemia in a greater proportion of children and in a shorter timeframe (serum potassium at 24 hours in ReSoMal group 4.0 vs. 3.2 in WHO-ORS group, p=0.001). ReSoMal also shortened time to rehydration in one study comparing ReSoMal with hypo-osmolar ORS.

As noted by one of the reviewers we included in the systematic review two trials that compare oral rehydration solutions with identical electrolyte/osmolarity) but are worthy of specific mention. Included in the first trial by Alam et al., 2009 as a comparator to standard ORS were two additional arms with either amylase-resistant starch or rice added to the glucose ORS. The second trial by Alam et al., 2015 compared hypo-osmolar WHO ORS to hyposmolar WHO ORS with added partially hydrolysed guar gum. The hypothesis being tested in these trials was whether these fermentable carbohydrates, that form short chain fatty acids in the colon, could improve gut barrier function by providing energy to the colon and improving overall metabolism and reduce the duration of diarrhoea. These have the potential to reduce overall stool volume and recovery time and could be considered as candidates for future trials in African children with mortality as a key endpoint.

Unlike the studies reported in Asia, diarrhoea comorbidity in African children hospitalised with SAM has a poor prognosis, with a case fatality rate of 18–20%. A large prospective study investigating risk factors for mortality in 1206 Kenyan children with SAM and diarrhoea at admission to hospital (≥3 watery stools/day) showed that both hyponatraemia and hypokalaemia were associated with a greater risk of mortality: hyponatraemia odds ratio 4.6 (95% CI 2.0,10.6, p<0.001) and hypokalaemia odds ratio 2.5 (95% CI 1.3, 4.6, p<0.004). Hyponatraemia has nearly twice the impact on risk of mortality when compared with hypokalaemia; therefore, it would be prudent to place the importance of sodium status ahead of potassium. By this deduction, there is no clear advantage of ReSoMal over standard or...
hypo-osmolar rehydration solutions in terms of sodium status. Conversely, there are risks of serious harm through development of symptomatic hyponatraemia.

These findings highlight the lack of compelling evidence to support the current rehydration guidelines for management of children with SAM complicated by diarrhoea. Hypo-osmolar solutions have no apparent benefit on sodium status, i.e. there is no significant difference in numbers with hyponatraemia after rehydration, but do have significant improvements on reduction of stool volume and frequency, and on duration of diarrhoea. It is unclear, however, whether this translates to a survival advantage. Just two of the studies reported on mortality, and no deaths were observed in either. The mortality rate in children with SAM and diarrhoea in African children is substantially higher than reported from the studies included in this review. It would therefore be useful to conduct similar trials in children in the African continent.

Reappraisal of current guidelines
The WHO reviewed the guidelines for management of SAM in 2013 and identified five papers (four of which have been included in this review). The review discusses evidence presented by the papers and, despite universally ‘low quality of evidence’, continues to make ‘strong recommendations’: choosing only to amend the SAM management guidelines to allow the use of hypo-osmolar ORS and advise that ‘either ReSoMal OR half strength standard WHO low-osmolarity oral rehydration solution with added potassium and glucose should be given’ to children with some or severe dehydration. The review also emphasises that ReSoMal ‘should not be given if children are suspected of having cholera or profuse watery diarrhoea’.

Application of guidelines
In practice, according to the WHO guidelines for management of children with SAM and diarrhoea, after the first two hours ReSoMal should be alternated hourly with F75, a specialised feeding formula for children with SAM (see Table 1). These are largely based on expert opinion and not on experimental evidence. The rehydration guidelines do not offer a pragmatic or evidence based approach to management of children with SAM complicated by dehydration and they are open to wide interpretation and misuse. Furthermore, for undernourished children with severe dehydration (equivalent of 10% or more loss of body weight), up to 20% of children hospitalised with gastroenteritis fulfil SAM anthropometric criteria for SAM (MUAC <11.5cm or WHZ <-3SD), but following rehydration they are reclassified as undernourished. Thus, the current recommendations have much wider implications with many ineligible children receiving potentially harmful low sodium rehydration solutions.

Conclusions
The available evidence for management of children with SAM and dehydration is limited and does not lend support to the WHO guidelines. There are arguments to support the use of hypo-osmolar ORS in children with SAM, but the currently recommended ReSoMal exposes children with SAM to risk of severe hyponatraemia. Further research should evaluate use of standard hypo-osmolar ORS in children with SAM, and assess optimal rates of rehydration in order to construct evidence based pragmatic guidelines that are designed for the context in which they will be used. In particular, it would be useful to conduct research in sub-Saharan Africa, given that none of the available evidence relates to this population.

Competing interests
No competing interest were declared.

Grant information
This work was supported by the Wellcome Trust [105603], an ISSF fellowship (Year 4 & 5 on 1st Oct 14 - 30 Sept 16, (2014 –2018)) awarded by Imperial College, London, to Dr K Houston; [203077], the KEMRI Wellcome Trust Programme East African Overseas Programme Award.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Supplementary material
Supplementary File 1: PRISMA checklist.
Click here to access the data.

References
PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Peer Review Status: ✔ ✔

Version 2

Reviewer Report 20 October 2017

https://doi.org/10.21956/wellcomeopenres.13842.r26515

© 2017 Briend A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

André Briend
Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark

This version of the manuscript is improved compared to the previous one and the author did take into account the points I made.

Two few minor points need correction:

a) In the discussion, the authors say:

All of the study interventions were blinded to patients and clinicians except in the Kumar et al. (2015) trial.

The study by Alam et al (2009) was not blinded either. See the following sentence in the method section of this paper.

“The treatment could not be blinded to the people involved in the study because of visible differences in the ORS solutions”.

Table 3 describes the same study as double blinded. This should be corrected as well.

b) Further in the discussion the authors say:

“However, Kumar et al. (2015) used frequency of hyponatraemia as the primary outcome - an objective, qualitative outcome”.

Do they mean – an objective quantitative outcome?"

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.

Author Response 23 Oct 2017

Kathryn Maitland, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Thank you Professor Briend. We have made the suggested changes and have submitted the revised version (3).

Competing Interests: No competing interests declared

Version 1

Reviewer Report 04 September 2017

https://doi.org/10.21956/wellcomeopenres.13380.r25181

© 2017 Rytter M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Maren Johanne Heilskov Rytter
Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark

Comments to the authors:

This is an welcome, interesting and well-written review illustrating the sparse evidence underlying the current WHO recommendations for rehydration in children with SAM (as other treatments for SAM!), and points to important future studies to be done.

General comments:

The fact that no children died in the reviewed studies illustrates that the study population of Asian children is very different from the population of interest mentioned in the introduction (children with SAM and diarrhoea in Africa, with high mortality). This issue is discussed, but in addition to the differences already mentioned, it may be relevant to mention that Asian children more frequently have marasmus and less frequently kwashiorkor. Cholera is also likely to be more frequent in Asia (requiring higher Na in rehydration fluids), and HIV is less prevalent. This is likely to make SAM+ diarrhoea a totally different disease complex in African than in Asian children. This does not make the review less relevant, but underlines the conclusion that we know very little about what we do when treating very sick children.

It may be informative to explain the history of development of ReSoMal, “Standard-WHO-ORS” and “low-osmolarity ORS” (now endorsed by WHO, and therefore by most health staff considered Standard ORS), which (at least to me) has been a little confusing:
Standard ORS was mainly developed to treat cholera in the first place, and therefore had a relatively high Na content. ReSoMal was developed at a time when this high-Na ORS was used, due to (theoretical) concerns about malnutrition being prone to Na retention, greater K deficit and higher risk of hypoglycaemia in children with SAM (particularly in oedematous children), but as emphasised it was never formally tested whether it was indeed better.

Low-osmolar ORS was developed to reduce the intensity of diarrhoea in children, and has been shown to be successful in that respect (see https://www.ncbi.nlm.nih.gov/pubmed/11869639) (although probably less appropriate for children with cholera, in whom Na loss is higher), and in most parts of the world low-osmolar ORS is now standard treatment for children with diarrhoea (and no malnutrition). This means that the ORS used for normal children is now closer in composition to ReSoMal regarding Na content than when this was developed. Notably, it also means that the osmolarity of ReSoMal is now higher than the ORS used for well nourished children, potentially increasing stool output in already very vulnerable children.

Another very practical problem with ReSoMal is what to do when ReSoMal is not available, which is the case for many primary care health facilities. Well-trained health staff will have learned that ORS should NEVER be given to malnourished children. Even though the WHO protocol has a recipe for ReSoMal made from ORS (including addition of potassium) my guess is that this “barrier of complication” makes necessary rehydration therapy unavailable for many children with SAM and dehydration seen in primary care.

As highlighted by the authors the evidence base underlying WHOs guidelines for SAM is generally poor, with few RCTs and a lot of expert opinion and pathophysiologic speculations. Some of the least poor evidence is (in my opinion) a from semi-observational studies where outcomes were compared in hospital facilities before and after implementation of a protocolised treatment package with some elements similar to the WHO guidelines. One of these, a study from Bangladesh compared outcomes before and after implementation of a treatment protocol for children with diarrhoea and SAM including early milk feeding, empiric antibiotics, emphasis on oral rehydration and slower initial rehydration. They found that children given protocolised treatment had almost half the risk of dying compared to children treated before the protocol was implemented. I know that your inclusion criteria was limited to RCTs, and therefore this study is not eligible, but it may be worthwhile to include in the discussion. Worth noting is that the rehydration solution used in both periods contained 90 mmol/l of sodium, higher than currently used low-osmolarity ORS, indication that good improvements in outcome can be obtained by relevant interventions while still giving higher sodium ORS than suggested by WHO guidelines. See https://www.ncbi.nlm.nih.gov/pubmed/10371570.

A quick search for experimental/laboratory/animal study data supporting the “well-established fact” that children with malnutrition have tendency to Na retention. Except for children with kwashiorkor (in whom this tendency is very obvious) I haven’t found any, which was a bit of a surprise (although I must admit that my search may not have been extensive enough). I wonder if it would be worthwhile to ask the people who wrote the WHO manual if they knew of laboratory or experimental data supporting the idea of Na and fluid retention (in non-oedematous children)?

I am a bit puzzled about the choice of primary outcome: The most important outcome should be
mortality, or something else of direct clinical relevance (like: clinical deterioration, convulsions, failure of oral therapy etc). It is of course also relevant to report other outcomes (like laboratory tests), bearing in mind that these are always surrogate markers for relevant health outcomes. Other similar outcomes to report could be hypo-kalemia, and hypo-glycemia (if these were reported by any studies). Even though they (as argued) may not have equal clinical significance, they should be reported in the result section and not in the discussion (as hypo-kalemia is now).

The studies associating hyponatremia with mortality are from Africa; and the included studies finding development of hyponatremia with rehydration are from Asia, where hyponatremia does not seem be associated with mortality (see for example: Chisti et al: Predictors of death in under-five children with diarrhoea admitted to a critical care ward in an urban hospital in Bangladesh, Acta Paediatrica 2011 3). So the suggested evidence for a causal links between low-sodium rehydration and mortality is indirect and a bit weak weak... The causes for developing hyponatriemia in African children may be different from the causes of hyponatremia in Asian children. Also, I am not sure that hyponatremia was neccesarily a cause of death in the African children, although associated with mortality, but a sign of severe disease. It is possible that correcting their hyponatriemia would not make their prognosis better, but simply be "biochemical make-up". Similarly, iatrogenic hyponatremia (although probably not a good thing) may not be caused by the same mechanisms as admission hyponatremia. Your concerns about hyponatremia is relevant, but maybe the weakness of surrogate markers should be discussed. The conclusion being be that a randomised trial among those who need better treatment the most is urgently needed. And with the high current mortality it is neccesary and realistic to use mortality as an outcome.

Specific points:

Page 3, first paragraph: It is not clear where the exact numbers come from: 49% with diarrhoea, 16% developing diarrhoea when admitted, mortality of 9% and 19%. It looks like they are derived from a specific study, but which one? Or are they averages from the four studies referenced? In any case I would not be so specific, but rather state that “...diarrhoea complicates around half of admissions for SAM...”

It would be helpful if the sodium contents of the different solutions could be incorporated into table 3 (although they are given in table 5), to appreciate the comparison.

Fluid therapy seems particularly tricky in children with oedema, and clinicians have varying approaches to this. In spite of this, the WHO protocol does not differentiate fluid therapy to oedematous and non-oedematous children, and is not very clear about diagnosing dehydration in these (overhydrated) children. It seems plausible that oedematous and non-oedematous children could require different strategies, but of course there is no evidence for this. In order to make this more clear future studies should report results separately for oedematous and non-oedematous children, and test any effect for interaction with oedema. Although I am aware that your included studies did not do this, it would be helpful if table 3 could specify how many children had oedematous malnutrition in each study?

References
Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Childhood malnutrition, paediatrics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 26 Sep 2017

Kathryn Maitland, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Please see our joint response

**Competing Interests:** No competing interests were disclosed.

Reviewer Report 21 August 2017

https://doi.org/10.21956/wellcomeopenres.13380.r25180

© 2017 Briend A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

André Briend
Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark
This is an important critical review of the evidence supporting the current WHO recommendation of using a low sodium high potassium solution (Resomal, 45 mmoles Na, 40 mmoles K) in children with diarrhoea and severe malnutrition. The paper is correct in highlighting that the strength of this evidence is very low, as acknowledged in the quoted 2013 WHO document. The conclusion of the paper, namely that a randomized study comparing the outcome of children treated with current low osmolarity WHO ORS and Resomal seems warranted. It could be argued however that with two randomised high quality studies suggesting that Resomal increases the risk of hyponatraemia, and none showing a clear benefit beyond better correction of hypokalaemia, a change of recommendation could already be considered. It could be recommended to test the current low osmolarity WHO ORS with added potassium (as in the Alam et al 2009 study) vs. resomal.

The paper has a clear focus on electrolyte disorders of children with diarrhoea and especially on the risk of hyponatraemia in relation to the sodium content of the rehydration solution. This is fine but in this case, one wonders whether two papers now included in the evidence base should not be excluded, namely the Alam 2009 and Alam 2015 papers. These two papers compare oral rehydration solutions with identical electrolyte content, and are not really relevant to the hypothesis discussed here. These two papers describe an attempt to decrease stool output and to improve nutritional recovery by the addition of ingredients (resistant starch or PHGG) acting as soluble fibres. The idea is that these ingredients will not be digested in the upper gut and will be fermented in the colon to form short chain fatty acids which provide some energy to the colon and overall metabolism and may reduce the duration of diarrhoea and help to improve nutritional recovery. Their main outcome is duration of diarrhoea and their secondary outcome is time to nutritional recovery which is quite different from recovery from dehydration or correction of electrolyte disorders. I would be in favour of removing these two studies from the evidence base. This would leave a clearer message, namely that ORS with 75 mmoles/L of sodium does not increase risk of hyponatraemia compared with ORS with 90 mmoles/L whereas hyponatraemia seems to be a problem when sodium is as low as 45 mmoles/L as in Resomal.

If the authors want to keep these two Alam et al. studies, they should broaden the discussion beyond electrolyte composition and discuss the evidence suggesting that some soluble fibres should be added as ingredient to the oral rehydration solutions.

The statement that there is no data on the risk of sodium overload in children suffering from severe malnutrition needs qualification. The current concern is based on an old paper from Uganda reporting an excess of heart failure in children receiving a high energy milk to which sodium was added, apparently to improve acceptability (See: Wharton et al., 1967). It can be argued that the quantity of sodium given to these children was presumably higher than those receiving low osmolarity ORS, also that these children received this high sodium milk for much longer that ORS is given, and also they had a high sodium intake in absence of diarrhoea, which means these findings cannot be extrapolated to children with diarrhoea, but this paper should be quoted. Also, there are observations suggesting that even Resomal given liberally to children in absence of diarrhoea can lead to an excess mortality due to heart failure which could be due to excessive sodium intake (See: Grellety Y, 2000). Arguably, this is again low quality evidence in favour of using low sodium rehydration solution in case of diarrhoea, but this should be mentioned as well.

Minor comments
The term “standard ORS” to refer to the old WHO solution (with 90 mmoles Na/L) is confusing, as this solution is no more recommended and the “low osmolarity ORS (Na 75 mmoles/L) is now the WHO standard. Choose another term avoiding the confusion, maybe just “old WHO ORS with 90 mmoles/L Na”.

Abstract:

Resomal contains 40 mmoles /L of potassium, not 20.

Discussion:

The authors say:

“ReSoMal also shortened time to rehydration in one study comparing ReSoMal with hypo-osmolar ORS”.

Reference?

“Unlike the studies reported in Asia, diarrhoea comorbidity in children hospitalised with SAM has a poor prognosis, with a case fatality rate of 18–20%.”

Clarify. Do you mean in Africa?

References

Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes

Are sufficient details of the methods and analysis provided to allow replication by others?
Yes

Is the statistical analysis and its interpretation appropriate?
Yes

Are the conclusions drawn adequately supported by the results presented in the review?
Yes

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 26 Sep 2017

Kathryn Maitland, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Please see our joint response

**Competing Interests:** No competing interests were disclosed.

---

**Comments on this article**

Version 1

Author Response 26 Sep 2017

Kathryn Maitland, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

Authors responses to Prof Briend and Dr Rytter

We thank the two reviewers for their very detailed and helpful comments. We have revised the paper to include

1/ Clearer indication of Old WHO ORS and Standard (hyposmolar) ORS which is currently being given; these have been changed in the manuscript and the titles of the tables.

2/ Included a section in the paper that explains the history of the Old WHO ORS and current Standard WHO ORS; and included and reported the references to the Cochrane review on ORS types. (Under the section headed **Types of Oral Rehydration Solutions**)

3/ Added and discussed the two references suggested by Professor Briend to the additional paper/thesis he suggested (Wharton and Grellety)

4/ Included a section in the paper that discussed the two trials that were included on the overall review, that highlights that we included in the systematic review two trials that compared compare oral rehydration solutions with identical electrolyte content (thus do not directly address the question of electrolyte/osmolarity) but are worthy of specific mention. And detail the two trials and conclude that these have the potential to reduce overall stool volume and recovery time and could be considered as candidates for future trials in African children with mortality as a key endpoint.

5/ We chose to use sodium and time to rehydration/length of diarrhoea as our major endpoints
since none of the Asian studies reported any mortalities. We were unsure of how many children had kwashiorkor as these were not reported in most of the trials.

We have made the corrections noted by Prof Briand and included relevant references where missing or more specific reference at the beginning reporting mortality (from one paper).

**Competing Interests:** We have no competing interests